🫧 Gut Health

KPV

KPV (Lys-Pro-Val)

Also called KPV, lysine-proline-valine, alpha-MSH 11-13

A three-amino-acid fragment studied for gut inflammation

KPV is three amino acids long, which makes it one of the smallest peptides anyone uses. It is the tail end of a natural anti-inflammatory hormone, and in preclinical work that tail carries much of the anti-inflammatory effect. It has been studied mainly in preclinical models of gut inflammation, with no human study, and it is not an approved medicine.

A three-amino-acid fragment snipped off the end of a hormone your body already makes. Almost every page describes it as switching on a melanocortin receptor; the research fairly clearly says it does not. What it appears to do instead is more interesting, and it is why nearly all the data are about the gut rather than skin. No human study of KPV has been published.

Route studied: Oral and other routes (preclinical studies)
Status: Not FDA-approved

Emerging Evidence

Human trials published, with more underway

58 papers · 3 clinical trials

See the research

What KPV has been studied for

The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.

Gut inflammation: The main research area, in preclinical colitis models. It gets into gut lining cells through a transporter those cells use to absorb small protein fragments from food, then turns down an inflammatory switch from the inside.
Skin: Turning up in topical and wound-care formulations. The skin research is cell culture only.
Mentioned with BPC-157: Often discussed together for the gut, on the argument that one acts on inflammation and the other on the lining. No study has tested the combination.

Mechanism of Action

How KPV works

KPV is three amino acids long. That is about as small as a peptide gets. It is the tail end of a larger hormone called alpha-MSH, the one best known for controlling pigment.

Because it comes from that hormone, nearly every page says it works by switching on the same receptors. The research says otherwise, and the evidence against is unusually clean.

Three reasons the popular explanation is wrong

The part of alpha-MSH that grips those receptors is not in KPV at all; it was left behind in the part that was cut off. When researchers measured the chemical signal those receptors produce when activated, KPV produced none. And in preclinical models whose receptor does not work, KPV kept working anyway.

Any one of those is awkward for the receptor story. Together they close it.

What it appears to do instead

KPV is small enough to be carried straight into a cell by the transporter the gut uses to absorb protein fragments from food. It does not knock on the door; it comes in through the delivery entrance.

Once inside, it interferes with inflammation at an unusual point. Inflammation runs through a master switch called NF-kB, which normally travels into the cell nucleus to start issuing orders. KPV appears to stop the messenger reaching the control room rather than switching the alarm off at source.

Why the research is about the gut

That transporter is a gut transporter. It is why the research is overwhelmingly about inflammatory bowel disease models, and why so much of it concerns oral delivery to the gut.

There is no in-vivo preclinical study of KPV on skin, and no human study of it at all.

KPV side effects: what studies reported

Little documented. The parent hormone causes skin darkening and flushing; KPV is the fragment that appears to have left those behind.

Reported outside trials

Mild stomach upset with oral use
Injection-site redness with injected use

Worth knowing

Unlike its parent hormone it does not appear to cause tanning or flushing

Source: Preclinical studies and reports outside trials; no human study. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about KPV belong with a licensed clinician who knows your history.

Your Genetics & KPV

The genes involved in how KPV works

KPV works through the receptors these genes build, and the genes vary from person to person. Researchers have linked some of that variation to differences in how people respond. A DNA report tells you which versions you carry.

Chromosome 16Melanocortin signaling

MC1R · ••

The Arg160Trp variant reduces MC1R function and is associated with red hair and fair skin. The research suggests KPV does not act mainly through MC1R, so this variant is pathway context only.

NOD2Innate immune sensing

NOD2 variants are among the best-established genetic risk factors for Crohn's disease. This one is often not readable on consumer arrays. No study has tested KPV in relation to NOD2 genotype.

Chromosome 19Gut mucosal defense

FUT2 · ••

Non-secretors (AA genotype) lack certain sugar coatings on the gut lining, which alters the microbiome and is associated with some gut conditions in human studies. That describes gut biology, not a response to KPV.

Chromosome 1Anti-inflammatory signaling

IL10 · ••

The -1082A>G variant has been associated with differences in IL-10 production, one of the body's anti-inflammatory signals. Pathway context only; untested with KPV.

The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.

Which of these variants do you carry?

Your report reads the DNA file you already have against this research.

Read my DNA, $99

Often discussed alongside

Compounds that come up next to KPV in research and discussion. Each has its own page. None of this is a suggestion to combine them.

BPC-157

also studied for the gutModerate Evidence

Body Protection Compound 157

BPC-157 comes up whenever people talk about injuries that will not heal: tendons, ligaments, a gut irritated by painkillers. It is a short chain of amino acids copied from part of a protein the stomach already makes, and the preclinical research on it is unusually consistent for this category: across many separate preclinical studies, injured tissue healed faster than it did without it. The gap is that this has largely not been repeated in people, and it is not an approved medicine, so no regulator checks the quality of what is sold under its name.

Gene variants

19+

Studies

GLP-2

the approved gut growth signalModerate Evidence

Glucagon-Like Peptide-2

GLP-2 is the signal the gut uses to repair and rebuild its lining, released every time you eat. The drug version, teduglutide (Gattex, Revestive), is one of the few compounds in this library that is an approved medicine. It is approved for short bowel syndrome in people who depend on intravenous feeding, where trials showed it reduced the amount of that feeding needed. It is not a supplement for a bloated stomach.

Gene variants

80+

Studies

Access

Access and legal status

KPV is not an FDA-approved drug. Products sold online as “research chemicals” are labelled not for human use, and FDA treats them as unapproved drugs when they are marketed for people. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.

Your DNA and KPV: see which of the variants studied alongside it you carry, and what that research does and does not show. Read my DNA, $99 →

Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.

Worth knowing about KPV

Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.

No human study: Everything known comes from cell culture and preclinical models. Its safety and effects in people have not been studied, and it is not an approved medicine.
It calms inflammation rather than fixing a cause: In preclinical models it dampens the inflammatory signal rather than addressing whatever is driving it. Gut inflammation needs a medical diagnosis.

The evidence behind KPV

Read the tissue, not just the result. Nearly all of this work is about the gut, because the transporter that carries KPV into cells is a gut transporter. There is no in-vivo preclinical study of KPV on skin and no human study of KPV at all. Papers using human cell lines are laboratory work, not human trials.

The literature, counted

58Papers indexed 14Preclinical 34Tagged human 3Clinical trials

Counted in PubMed on 3 August 2026 for KPV tripeptide. Every figure links to the search that produced it, so you can re-run it. “Tagged human” is not the same as a human trial: that tag also covers work on human cells and reviews discussing people, which is why the trial count is given separately.

Preclinical studies

2 of 2Preclinical results do not automatically hold in people.

Reviews

1 of 3Papers that gather other studies rather than run new ones.

Gastroenterology · 2008
Review
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al.
The paper explaining how KPV gets into cells: through PepT1, the transporter the gut uses to absorb protein fragments from food. It worked at very low concentrations, and the cells involved had none of the receptors KPV is usually said to activate.
Read the review
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation: source for KPV (opens in a new tab)

Every source behind this page52 more

Everything we cite for KPV, including preclinical work and early research. Each link goes to the source itself, so you can judge it rather than take our word for it.

Last updated 3 August 2026 · literature counts verified against PubMed on 3 August 2026

Frequently Asked Questions

What has KPV been studied for?

Gut inflammation, in cell culture and preclinical colitis models, where it reduced inflammatory signalling. It enters gut cells through the PepT1 transporter and appears to act on NF-kB inside the cell rather than through melanocortin receptors. No human study has been published.

Do genes affect KPV response?

No study has tested whether any genotype changes response to KPV. NOD2 and FUT2 variants are associated with gut conditions in human studies, and MC1R is the receptor of its parent hormone, which KPV appears not to rely on. A DNA report can show which versions you carry and what that research does and does not show.

Why does oral delivery come up so often with KPV?

Because it is a tripeptide small enough to be carried by the gut's own peptide transporter, and its research target is the gut lining. Researchers have built oral delivery systems for it in preclinical colitis studies. Human data on oral KPV do not exist.

Watch

What clinicians and researchers say about KPV

All 6 talks on KPV

20 minExposing The Truth About PeptidesDoctor Mike · ClinicianBPC-157TB-500KPV

19 minLearn Peptides So Fast it's UNREALAshley Froese · EducatorGHK-CuKPVThymosin Alpha-1

6 minDoctor Explains 20 Most Powerful PeptidesAshley Froese · EducatorSemaglutideTirzepatideRetatrutide

Learn more about KPV

comparisons

In depth

KPV vs LL-37: what the research found, and why LL-37 cuts both ways in skin disease

9 min read

peptide guides

In depth

What the research says about your variants.

The report

Which KPV variants do you carry?

Your report reads the DNA file you already have against the published research on 31 peptides, marker by marker, and says what that research does and does not show.